BRCA1/2 mutations were observed in 1–2% CCA samples, and Rizzo et al. [12] reported 1–7% of BRAC1/2 mutations in BTC samples, associated with poor response to standard treatments. Here, BRCA1 is linked to cholangiocarcinoma.